Cost-utility analysis of ¹⁷⁷Lu-PSMA-617 radioligand therapy in second-line and third-line treatment for metastatic castration-resistant prostate cancer (mCRPC) in Germany.

ABSTRACT:

Purpose

To evaluate the cost-effectiveness of ¹⁷⁷Lu-PSMA-617 radioligand therapy (PRLT) in metastatic castration-resistant prostate cancer (mCRPC) in Germany by comparing (I) PRLT plus standard-of-care (SoC) versus SoC alone as third-line treatment and (II) PRLT versus second-line cabazitaxel chemotherapy.

Methods

Cohort state-transition models were developed with (I) four health states (treatment, stable after treatment, progression, death) and (II) six health states (treatment, stable after treatment, third-line treatment after progression, stable after third-line treatment, next progression, death). Transition probabilities were derived from the VISION and TheraP trials, and quality-of-life data from the VISION and CARD trials. Costs were derived from statutory

SUBMITTER: Brinkmann C 

PROVIDER: S-EPMC12491114 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature